S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
The single greatest medical breakthrough of all time? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
The single greatest medical breakthrough of all time? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
The single greatest medical breakthrough of all time? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
The single greatest medical breakthrough of all time? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
The single greatest medical breakthrough of all time? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
The single greatest medical breakthrough of all time? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
The single greatest medical breakthrough of all time? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
The single greatest medical breakthrough of all time? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:PGNY

Progyny (PGNY) Stock Forecast, Price & News

$33.09
-0.16 (-0.48%)
(As of 09/22/2023 ET)
Compare
Today's Range
$32.94
$33.55
50-Day Range
$33.09
$42.90
52-Week Range
$28.03
$45.98
Volume
808,454 shs
Average Volume
692,785 shs
Market Capitalization
$3.16 billion
P/E Ratio
67.53
Dividend Yield
N/A
Price Target
$49.43

Progyny MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
49.4% Upside
$49.43 Price Target
Short Interest
Bearish
6.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of Progyny in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$122.90 M Sold Last Quarter
Proj. Earnings Growth
25.93%
From $0.54 to $0.68 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

69th out of 968 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

2nd out of 7 stocks


PGNY stock logo

About Progyny (NASDAQ:PGNY) Stock

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Price History

PGNY Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Progyny (NASDAQ:PGNY) PT Raised to $48.00
Check Out What Whales Are Doing With PGNY
3 Reasons Growth Investors Will Love Progyny (PGNY)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Here’s Why Progyny (PGNY) Outperformed in Q2
TPG GP A, LLC Reduces Stake in Progyny Inc
Truist Financial Sticks to Their Buy Rating for Progyny (PGNY)
The Latest Analyst Ratings for Progyny
Progyny Unveils Nationwide Access to Menopause Care
Progyny, Inc. Announces Second Quarter 2023 Results
Progyny (PGNY) Beats Q2 Earnings and Revenue Estimates
See More Headlines
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

PGNY Company Calendar

Last Earnings
8/03/2023
Today
9/23/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PGNY
Fax
N/A
Employees
393
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$49.43
High Stock Price Forecast
$62.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+49.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$30.36 million
Pretax Margin
5.14%

Debt

Sales & Book Value

Annual Sales
$786.91 million
Cash Flow
$0.33 per share
Book Value
$4.06 per share

Miscellaneous

Free Float
81,763,000
Market Cap
$3.16 billion
Optionable
Not Optionable
Beta
1.51

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. David J. SchlangerMr. David J. Schlanger (Age 64)
    Exec. Chairman
    Comp: $510.41k
  • Mr. Peter Anevski (Age 56)
    CEO & Director
    Comp: $1.01M
  • Mr. Michael Sturmer (Age 46)
    Pres
    Comp: $761.5k
  • Mr. Mark S. Livingston (Age 57)
    Chief Financial Officer
    Comp: $693.87k
  • Ms. Allison Swartz (Age 33)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $173.35k
  • Mr. James Hart
    VP of Investor Relations
  • Ms. Risa Fisher
    Exec. VP & Chief Marketing Officer
  • Ms. Cassandra Pratt
    Sr. VP of People
  • Ms. Julie Stadlbauer
    Exec. VP of Strategic Sales & Partnerships
  • Ms. Janet Choi M.D.
    Member of the Medical Advisory Board & Chief Medical Officer













PGNY Stock - Frequently Asked Questions

Should I buy or sell Progyny stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PGNY shares.
View PGNY analyst ratings
or view top-rated stocks.

What is Progyny's stock price forecast for 2023?

6 equities research analysts have issued twelve-month price targets for Progyny's shares. Their PGNY share price forecasts range from $34.00 to $62.00. On average, they predict the company's share price to reach $49.43 in the next year. This suggests a possible upside of 49.4% from the stock's current price.
View analysts price targets for PGNY
or view top-rated stocks among Wall Street analysts.

How have PGNY shares performed in 2023?

Progyny's stock was trading at $31.15 at the beginning of 2023. Since then, PGNY stock has increased by 6.2% and is now trading at $33.09.
View the best growth stocks for 2023 here
.

When is Progyny's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PGNY earnings forecast
.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) released its earnings results on Thursday, August, 3rd. The company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.05. The business earned $279.40 million during the quarter, compared to the consensus estimate of $261.91 million. Progyny had a trailing twelve-month return on equity of 12.19% and a net margin of 5.15%. The company's quarterly revenue was up 43.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.09 earnings per share.

What guidance has Progyny issued on next quarter's earnings?

Progyny updated its FY23 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $0.50-$0.53 for the period, compared to the consensus earnings per share estimate of $0.47. The company issued revenue guidance of $1.075-$1.09 billion, compared to the consensus revenue estimate of $1.06 billion.

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).

When did Progyny IPO?

(PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

What is Progyny's stock symbol?

Progyny trades on the NASDAQ under the ticker symbol "PGNY."

Who are Progyny's major shareholders?

Progyny's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (10.02%), KPCB XIII Associates LLC (5.38%), Clearbridge Investments LLC (4.24%), JPMorgan Chase & Co. (2.80%), State Street Corp (2.68%) and Thrivent Financial for Lutherans (2.38%). Insiders that own company stock include Beth C Seidenberg, Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Lisa Greenbaum, Mark S Livingston, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Progyny's stock price today?

One share of PGNY stock can currently be purchased for approximately $33.09.

How much money does Progyny make?

Progyny (NASDAQ:PGNY) has a market capitalization of $3.16 billion and generates $786.91 million in revenue each year. The company earns $30.36 million in net income (profit) each year or $0.49 on an earnings per share basis.

How many employees does Progyny have?

The company employs 393 workers across the globe.

How can I contact Progyny?

Progyny's mailing address is 1359 BROADWAY, NEW YORK NY, 10018. The official website for the company is www.progyny.com. The company can be reached via phone at 212-888-3124 or via email at investors@progyny.com.

This page (NASDAQ:PGNY) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -